Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on delivering therapeutics through effective oral delivery, announced today that it has received revised regulatory guidance for LPCN ...

Colorado's cannabis testing loopholes have led to consumers being deceived about the safety of the products they buy, with ...

In November, virologist Beata Halassy announced to the world that she had cured her own breast cancer using a treatment ...

Bushra Sumra's career highlights the profound impact that expertise in clinical research and regulatory compliance can have on advancing treatments for rare diseases.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

The U.S. Food and Drug Administration (FDA) issued a final guidance for industry titled Action Levels for Lead in Processed Food Intended for ...

President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from his new ...

Debra Patt, MD, PhD, MBA, MPH, warns that prior authorization barriers are delaying critical cancer treatments and urges a ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.

Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.

Research by the George Institute for Global Health underscores the need for robust regulatory frameworks for e-pharmacies in low- and middle-income countries to ensure safety and quality. The study ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.